AIGENE, INC.

Medtech · Private

High-efficiency urine cell-free DNA (ucfDNA) extraction and analysis platform for disease screening and monitoring

Grants
$350K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · uProcess: A novel home and lab system to improve cfDNA screening and monitoring using transrenal DNA$349,890
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1707SANSIMEON, INC——
1708NEPHSMART LLC——
1709ZENALUX BIOMEDICAL, INC.——
1710AIGENE, INC.——
1711NANOFIBER SOLUTIONS LLC——
1712Symic Bio, Inc.——
1713MaGPaD, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Methods For The Rapid Assessment Of The Efficacy Of Cancer Therapy And Related Applicationsapplication
  • Devices And Methods Related To Collection Of Cell-free Dnaapplication
  • Systems, Compositions, And Methods For Cancer Dna Detectionapplication
  • Systems, Compositions, And Methods For Cancer Dna Detectionapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.